Medpace Q1 Beats Expectations, Despite Cancellation Woes

Medpace Holdings exceeded Wall Street expectations in Q1 2026, with revenue up 26.5% to $706.6M, beating estimates by 1.5%. Earnings per share hit $4.28, topping forecasts by 10.2%. Adjusted EBITDA came in at $149.4M, an 8.2% beat. Guidance for the full year remains at $2.81B in revenue and $17.09 in earnings per share. Organic revenue grew 25.8% year over year, and operating margins stayed flat at 20%. Higher project cancellations, mainly in oncology and cardiovascular trials, dragged the book-to-bill ratio down to 0.88. Medpace is focusing on pipeline growth and win rates, while hiring continues amid investments in AI and efficiency. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/570a24331fe76685